Recipharm, a contract development and manufacturing organization (CDMO), and Exela Pharma Sciences, a US-based client-centric CDMO, have entered an exclusive strategic alliance aimed at enhancing sterile manufacturing capabilities in the United States.
 
This collaboration will provide Recipharm with access to Exela’s manufacturing facility located in Lenoir, North Carolina. The facility, accredited by the FDA (CDER and CBER), has a proven track record of delivering “light speed” projects during the COVID-19 pandemic. The site manufactures sterile injectable pharmaceuticals in vial and pre-filled syringe (PFS) formats.
 
Exela’s facility enables Recipharm to expand its sterile manufacturing capacity in the US, offering the availability of over 100 million units production capacity for customers. Also, the site is extending into producing highly targeted biopharmaceutical drugs, such as Antibody Drug Conjugates (ADCs), GLP-1 drugs and other sterile products, such as vaccines and biologics.
 
Recipharm will add to Exela’s capabilities by offering its robust analytical capabilities, commercial expertise and Manufacturing Science and Technology (MSAT) support. Additionally, ReciBioPharm, its biologics division, will contribute to the collaboration with its advanced therapeutic medicinal products (ATMP) capabilities.
  
Greg Behar, CEO of Recipharm said: “We are excited about this strategic alliance with Exela, which significantly enhances our manufacturing footprint in the US. This partnership aligns with our commitment to provide high-quality manufacturing solutions and expand our capabilities in the production of sterile products, such as GLP1, peptides, biologics, ADCs and other critical pharmaceuticals.”
 
Phanesh Koneru, Ph.D., LL.M., President & CEO of Exela, stated: “Recipharm is a highly respected CDMO with world-wide reach. We are honoured and excited to be Recipharm’s exclusive US partner. This collaboration offers a unique and efficient CDMO platform for biopharma customers that seek to participate in both US and EU markets and are looking for scale, speed and versatility with experience in delivering complex projects.”